EA201790946A1 - Способы и композиции, связанные с функциональными полипептидами, встроенными в гетерологичные белковые каркасы - Google Patents

Способы и композиции, связанные с функциональными полипептидами, встроенными в гетерологичные белковые каркасы

Info

Publication number
EA201790946A1
EA201790946A1 EA201790946A EA201790946A EA201790946A1 EA 201790946 A1 EA201790946 A1 EA 201790946A1 EA 201790946 A EA201790946 A EA 201790946A EA 201790946 A EA201790946 A EA 201790946A EA 201790946 A1 EA201790946 A1 EA 201790946A1
Authority
EA
Eurasian Patent Office
Prior art keywords
framework
methods
embedded
functional derivatives
functional polypeptides
Prior art date
Application number
EA201790946A
Other languages
English (en)
Other versions
EA201790946A8 (ru
Inventor
Инцзи Пэн
Ричард А. Лернер
Роналд М. Линдсей
Original Assignee
Зе Скриппс Рисёрч Инститьют
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зе Скриппс Рисёрч Инститьют filed Critical Зе Скриппс Рисёрч Инститьют
Publication of EA201790946A1 publication Critical patent/EA201790946A1/ru
Publication of EA201790946A8 publication Critical patent/EA201790946A8/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящем изобретении предложены способы получения функциональных производных эффекторных полипептидов (например, гормонов и лигандов рецепторов), встроенных в различные белковые каркасы (например, каркасы антител). Указанные способы включают модификацию эффекторного полипептида комбинаторной библиотекой концевых линкерных последовательностей, введение указанных модифицированных последовательностей в каркас-носитель и последующий отбор функциональных производных из библиотеки модифицированных последовательностей полипептидов, встроенных в каркас-носитель. В качестве иллюстративных примеров согласно настоящему изобретению также предложены конкретные функциональные производные лептина, оцФСГ и оцРелаксина, встроенные в каркас антитела, а также варианты терапевтического применения таких функциональных гибридных молекул.
EA201790946A 2014-12-01 2015-12-01 Способы и композиции, связанные с функциональными полипептидами, встроенными в гетерологичные белковые каркасы EA201790946A8 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462085807P 2014-12-01 2014-12-01
US201562222384P 2015-09-23 2015-09-23
PCT/US2015/063126 WO2016089829A1 (en) 2014-12-01 2015-12-01 Methods and compositions related to functional polypeptides embedded in heterologous protein scaffolds

Publications (2)

Publication Number Publication Date
EA201790946A1 true EA201790946A1 (ru) 2018-04-30
EA201790946A8 EA201790946A8 (ru) 2018-10-31

Family

ID=56092310

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790946A EA201790946A8 (ru) 2014-12-01 2015-12-01 Способы и композиции, связанные с функциональными полипептидами, встроенными в гетерологичные белковые каркасы

Country Status (11)

Country Link
US (1) US10941188B2 (ru)
EP (1) EP3227477A4 (ru)
JP (1) JP2017536833A (ru)
CN (1) CN107208315A (ru)
AU (1) AU2015355191B2 (ru)
BR (1) BR112017011457A2 (ru)
CA (1) CA2969220A1 (ru)
EA (1) EA201790946A8 (ru)
IL (1) IL252410A0 (ru)
MX (1) MX2017007393A (ru)
WO (1) WO2016089829A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
CA3078460A1 (en) 2017-10-04 2019-04-11 Opko Pharmaceuticals, Llc Articles and methods directed to personalized therapy of cancer
TW202016125A (zh) * 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
WO2022061292A2 (en) * 2020-09-21 2022-03-24 The Board Of Regents Of The University Of Texas System Therapeutic agents and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2102339A2 (en) * 2007-01-12 2009-09-23 Sea Lane Biotechnologies,llc. Combinatorial libraries of conformationally constrained polypeptide sequences
US20110243943A1 (en) * 2010-04-02 2011-10-06 Athena Discovery, Inc. Treatment using relaxin-fusion proteins with extended in vivo half-lives
US20140050720A1 (en) * 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP2825653A4 (en) * 2012-03-14 2016-01-20 Innovative Targeting Solutions Inc PRODUCTION OF TARGETED SEQUENCE DIVERSITY IN FUSION PROTEINS
EP2890836B1 (en) * 2012-08-31 2019-07-17 The Scripps Research Institute Methods related to modulators of eukaryotic cells
US9644021B2 (en) * 2013-01-11 2017-05-09 The California Institute For Biomedical Research Bovine fusion antibodies
EP2968546B1 (en) * 2013-03-15 2023-09-20 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same

Also Published As

Publication number Publication date
JP2017536833A (ja) 2017-12-14
AU2015355191A1 (en) 2017-06-08
IL252410A0 (en) 2017-07-31
MX2017007393A (es) 2020-02-24
CN107208315A (zh) 2017-09-26
BR112017011457A2 (pt) 2018-04-03
WO2016089829A1 (en) 2016-06-09
EA201790946A8 (ru) 2018-10-31
US10941188B2 (en) 2021-03-09
EP3227477A4 (en) 2018-05-09
US20180298051A1 (en) 2018-10-18
EP3227477A1 (en) 2017-10-11
AU2015355191B2 (en) 2020-04-30
CA2969220A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
CY1124867T1 (el) Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
MX2022001222A (es) Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos.
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
EA202091198A1 (ru) Полипептиды, содержащие домен d, и их применение
TN2015000247A1 (en) Bcma antigen binding proteins
EA201891420A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
EA201591814A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОЛЕКУЛЫ Fc
MY186708A (en) Constructs targeting afp peptide/mhc complexes and uses thereof
EA201790248A1 (ru) Композиции носитель-антитело и способы их получения и применения
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
EA201690529A1 (ru) Способы модификации клетки-хозяина
EA201990321A1 (ru) Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123
BR112017006598A2 (pt) anticorpo de repetições antidipeptídeo derivado de ser humano (dprs)
EA201790946A8 (ru) Способы и композиции, связанные с функциональными полипептидами, встроенными в гетерологичные белковые каркасы
BR112016014913A8 (pt) anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado
UA117493C2 (uk) Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання
MX2021001418A (es) Produccion de proteinas heteromultimericas usando celulas de mamifero.
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
EA201992348A1 (ru) АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1
EA201790725A1 (ru) Основанные на близости расположения способы выбора партнеров для связывания
MX2016006586A (es) Identificacion de una citocina de linfocitos b novedosa.
EA201990927A1 (ru) Антитела против lag-3 и способы их применения
EA201792665A1 (ru) Антитела против ctla-4 и способы их применения
EA201892804A1 (ru) Антитела против tim-3 и способы их применения